Showing results (11-20 of 60) with videos related to
Sort By:
Pageof 6
Stem Cell Research & Therapy|January 11, 2014
Inhibition of mesenchymal stromal cells by pre-activated lymphocytes and their culture mediaErica Valencic, Claudia Loganes, Stefania Cesana, et al.Transfusion|June 3, 2008
Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation devicePaolo Perseghin, Giovanna D'Amico, Erica Dander, et al.Haematologica|March 7, 2007
Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignanciesEttore Biagi, Virna Marin, Greta Maria Paola Giordano Attianese, et al.Journal of Medical Case Reports|October 16, 2009
Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: a case reportChiara Beretta, Veronica Leoni, Mario Renato Rossi, et al.Human Gene Therapy Methods|November 29, 2012
Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cellsVirna Marin, Elisabetta Cribioli, Brian Philip, et al.Human Gene Therapy|December 15, 2016
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human StudiesMaria Caterina Rotiroti, Silvia Arcangeli, Monica Casucci, et al.Italian Journal of Pediatrics|September 24, 2011
New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near futureEttore Biagi, Virna Marin, Greta Maria Paola Giordano Attianese, et al.Neuropharmacology|November 20, 2013
Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brainFrancesca Pischiutta, Giovanna D'Amico, Erica Dander, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 2, 2007
Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactinHeidi V Russell, Douglas Strother, Zhuyong Mei, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 4, 2008
A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastomaHeidi V Russell, Douglas Strother, Zhuyong Mei, et al.Pageof 6